Eli Lilly is trading at ARS 40,800, up 6.81%, after Q3 revenue beat estimates and the company raised its full-year outlook.
- Q3 2026 revenue rose 39% to $24.4 billion.
- U.S. Zepbound revenue increased 48% to $5.3 billion as strong demand helped drive results.
- Positive Phase 3 data showed retatrutide delivered up to 20.9% weight loss, more than twice the Ozempic result in the trial. Broader market weakness does not explain the gain.